

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

14-3-3 sigma [1.T.28] antibody

RRID:AB_373069

Type: Antibody

Proper Citation

GeneTex Cat# GTX14122, RRID:AB_373069

Antibody Information

URL: http://antibodyregistry.org/AB_373069

Proper Citation: GeneTex Cat# GTX14122, RRID:AB_373069

Target Antigen: 14-3-3 sigma [1.T.28] antibody

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued; manufacturer recommendations: WB: Use at a concentration of 0.5 µg/ml. GTX14122 detects 20µg of reduced EGF-stimulated A431 cell lysate, visualized using a goat anti-mouse secondary antibody conjugated to HRP and a chemiluminescence detection system. Predicted molecular weight: 30 kDa. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user., Western Blot. The usefulness of this product in other applications has not been determined., WB; Western Blot; Immunohistochemistry

Antibody Name: 14-3-3 sigma [1.T.28] antibody

Description: This monoclonal targets 14-3-3 sigma [1.T.28] antibody

Target Organism: rat, mouse, human

Antibody ID: AB_373069

Vendor: GeneTex

Catalog Number: GTX14122

Record Creation Time: 20250820T000644+0000

Record Last Update: 20250820T072421+0000

Ratings and Alerts

No rating or validation information has been found for 14-3-3 sigma [1.T.28] antibody.

Warning: Discontinued at GeneTex

Discontinued; manufacturer recommendations: WB: Use at a concentration of 0.5 µg/ml. GTX14122 detects 20µg of reduced EGF-stimulated A431 cell lysate, visualized using a goat anti-mouse secondary antibody conjugated to HRP and a chemiluminescence detection system. Predicted molecular weight: 30 kDa. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user., Western Blot. The usefulness of this product in other applications has not been determined., WB; Western Blot; Immunohistochemistry

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Nandi SK, et al. (2022) Kaempferol attenuates viability of ex-vivo cultured post-NACT breast tumor explants through downregulation of p53 induced stemness, inflammation and apoptosis evasion pathways. Pathology, research and practice, 237, 154029.

Nandi SK, et al. (2022) Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil. Toxicology and applied pharmacology, 437, 115887.